Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 27, Issue , 2016, Pages V1-V27

  Novello, S ^a   Barlesi, F ^b   Califano, R ^c,d   Cufer, T ^e   Ekman, S ^f   Levra, M Giaj ^g   Kerr, K ^h   Popat, S ⁱ   Reck, M ^j   Senan, S ^k   Simo, G V ^l   Vansteenkiste, J ^m   Peters, S ⁿ   on behalf of the ESMO Guidelines Committee, ^o  

^a UNIVERSITY OF TURIN   (Italy)

^b AIX MARSEILLE UNIVERSITY   (France)

^c CHRISTIE HOSPITAL   (United Kingdom)

^d MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^e UNIVERSITY CLINIC OF RESPIRATORY AND ALLERGIC DISEASES   (Slovenia)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^g GRENOBLE UNIVERSITY HOSPITAL   (France)

^h UNIVERSITY OF ABERDEEN   (United Kingdom)

ⁱ ROYAL MARSDEN HOSPITAL   (United Kingdom)

^j Member of the German Center for Lung Research   (Germany)

^k VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^l HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^m UNIVERSITY HOSPITALS LEUVEN   (Belgium)

ⁿ LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^o ESMO HEAD OFFICE   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; ALECTINIB; ANAPLASTIC LYMPHOMA KINASE; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CRIZOTINIB; DENOSUMAB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; NAVELBINE; NECITUMUMAB; NINTEDANIB; NIVOLUMAB; PACLITAXEL; PEMBROLIZUMAB; PEMETREXED; PLACEBO; RAMUCIRUMAB; TAXANE DERIVATIVE; ZOLEDRONIC ACID;

ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; FOLLOW UP; HUMAN; MAINTENANCE CHEMOTHERAPY; METASTASIS POTENTIAL; MINIMALLY INVASIVE PROCEDURE; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; TREATMENT RESPONSE;

EID: 84992630838     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw326     Document Type: Article

References (183)

1. Jemal A, Bray F, Center MM et al. Global cancer statistics. CA Cancer J Clin 2011: 61: 69-90.
2. Torre LA, Bray F, Siegel RL et al. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65: 87-108.
3. Malvezzi M, Bertuccio P, Rosso T et al. European cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women? Ann Oncol 2015; 26: 779-786.
4. GLOBOCAN. 2012 Cancer incidence, mortality and prevalence worldwide [database online]. http://www-dep.iarc.fr/ (11 January 2016, date last accessed).
5. Howlader NNA, Krapcho M et al. SEER Cancer Statistics Review, 1975-2010. Bethesda, MD: National Cancer Institute 2013. http://seer.cancer.gov/ (11 January 2016, date last accessed).
6. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016; 66: 7-30.
7. Thomas A, Chen Y, Yu T et al. Trends and characteristics of young non-small cell lung cancer patients in the United States. Front Oncol 2015; 5: 113.
8. Forman D, Bray F, Brewster DH et al. Cancer Incidence in Five Continents. Lyon, France: IARC Press 2013.
9. Jemal A, Ma J, Rosenberg PS et al. Increasing lung cancer death rates among young women in southern and midwestern states. J Clin Oncol 2012; 30: 2739-2744.
10. International Agency for Research on Cancer (IARC). http://www.iarc.fr/ (13 Jan 2016, date last accessed).
11. Straif K, Cohen A, Samet J. Air Pollution and Cancer, IARC Scientific Publication No. 161. Lyon, France: IARC Press 2013; 161.
12. Hung RJ, McKay JD, Gaborieau V et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 2008; 452: 633-637.
13. Wang Y, Broderick P, Webb E et al. Common 5p15.33 and 6p21.33 variants influence lung cancer risk. Nat Genet 2008; 40: 1407-1409.
14. Novello S, Stabile LP, Siegfried JM. Gender-related differences in lung cancer. In Pass HI, Scagliotti GV, Ball D (eds), The IASLC Multidisciplinary Approach to Thoracic Oncology. Aurora, CO: IASLC Press 2014; p. 45-67.
15. McCarthy WJ, Meza R, Jeon J, Moolgavkar SH. Chapter 6: lung cancer in never smokers: epidemiology and risk prediction models. Risk Anal 2012; 32(Suppl. 1): S69-S84.
16. Toh CK, Gao F, Lim WT et al. Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity. J Clin Oncol 2006; 24: 2245-2251.
17. Couraud S, Souquet PJ, Paris C et al. BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokers. Eur Respir J 2015; 45: 1403-1414.
18. Travis WD, Brambilla E, Burke AP et al. (eds). WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart, 4th edition. Lyon, France: IARC Press 2015.
19. Sequist LV, Waltman BA, Dias-Santagata D et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011; 3: 75ra26.
20. Kerr KM, Bubendorf L, Edelman MJ et al. Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. Ann Oncol 2014; 25: 1681-1690.
21. Lee JK, Hahn S, Kim DW et al. Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis. JAMA 2014; 311: 1430-1437.
22. Rekhtman N, Paik PK, Arcila ME et al. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res 2012; 18: 1167-1176.
23. Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363: 1693-1703.
24. Shaw AT, Yeap BY, Mino-Kenudson M et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009; 27: 4247-4253.
25. Lindeman NI, Cagle PT, Beasley MB et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 2013; 8: 823-859.
26. McCourt CM, McArt DG, Mills K et al. Validation of next generation sequencing technologies in comparison to current diagnostic gold standards for BRAF, EGFR and KRAS mutational analysis. PLoS ONE 2013; 8: e69604.
27. Frampton GM, Fichtenholtz A, Otto GA et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 2013; 31: 1023-1031.
28. Barlesi F, Mazieres J, Merlio J-P et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet 2016; 387: 1415-1426.
29. Marchetti A, Di Lorito A, Pace MV et al. ALK protein analysis by IHC staining after recent regulatory changes: a comparison of two widely used approaches, revision of the literature, and a new testing algorithm. J Thorac Oncol 2016; 11: 487-495.
30. Viola P, Maurya M, Croud J et al. A validation study for the use of ROS1 immunohistochemical staining in screening for ROS1 translocations in lung cancer. J Thorac Oncol 2016; 11: 1029-1039.
31. Grunnet M, Sorensen JB. Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer 2012; 76: 138-143.
32. Kuhn MJ, Hammer GM, Swenson LC et al. MRI evaluation of "solitary" brain metastases with triple-dose gadoteridol: comparison with contrast-enhanced CT and conventional-dose gadopentetate dimeglumine MRI studies in the same patients. Comput Med Imag Graph 1994; 18: 391-399.
33. Wu Y, Li P, Zhang H et al. Diagnostic value of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography for the detection of metastases in non-small-cell lung cancer patients. Int J Cancer 2013; 132: E37-E47.
34. Chang MC, Chen JH, Liang JA et al. Meta-analysis: comparison of F-18 fluorodeoxyglucose-positron emission tomography and bone scintigraphy in the detection of bone metastasis in patients with lung cancer. Acad Radiol 2012; 19: 349-357.
35. Darling GE, Maziak DE, Inculet RI et al. Positron emission tomography-computed tomography compared with invasive mediastinal staging in non-small cell lung cancer: results of mediastinal staging in the early lung positron emission tomography trial. J Thorac Oncol 2011; 6: 1367-1372.
36. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
37. Goldstraw P, Chansky K, Crowley J et al. The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol 2016; 11: 39-51.
38. Ung KA, Campbell BA, Duplan D et al. Impact of the lung oncology multidisciplinary team meetings on the management of patients with cancer. Asia Pac J Clin Oncol 2016; 12: e298-e304.
39. Baser S, Shannon VR, Eapen GA et al. Smoking cessation after diagnosis of lung cancer is associated with a beneficial effect on performance status. Chest 2006; 130: 1784-1790.
40. Hughes AN, O'Brien MER, Petty WJ et al. Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers. J Clin Oncol 2009; 27: 1220-1226.
41. Rowland C, Danson SJ, Rowe R et al. Quality of life, support and smoking in advanced lung cancer patients: a qualitative study. BMJ Support Palliat Care 2016; 6: 35-42.
42. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 311: 899-909.
43. Burdett S, Stephens R, Stewart L et al. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 2008; 26: 4617-4625.
44. Delbaldo C, Michiels S, Syz N et al. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA 2004; 292: 470-484.
45. Pujol JL, Barlesi F, Daurès JP. Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials. Lung Cancer 2006; 51: 335-345.
46. Park JO, Kim SW, Ahn JS et al. Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer. J Clin Oncol 2007; 25: 5233-5239.
47. Rossi A, Chiodini P, Sun JM et al. Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncol 2014; 15: 1254-1262.
48. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-98.
49. Ardizzoni A, Boni L, Tiseo M et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 2007; 99: 847-857.
50. Socinski MA, Bondarenko I, Karaseva NA et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol 2012; 30: 2055-2062.
51. Paz-Ares L, Mezger J, Ciuleanu TE et al. Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-smallcell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study. Lancet Oncol 2015; 16: 328-337.
52. Thatcher N, Hirsch FR, Luft AV et al. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol 2015; 16: 763-774.
53. Paz-Ares L, Socinski MA, Shahidi J et al. 1320_PR: subgroup analyses of patients with epidermal growth factor receptor (EGFR)-expressing tumors in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabinecisplatin (GC) plus necitumumab (N) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC). J Thorac Oncol 2016; 11(4 Suppl): S153.
54. Li M, Zhang Q, Fu P et al. Pemetrexed plus platinum as the first-line treatment option for advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials. PLoS ONE 2012; 7: e37229.
55. Scagliotti GV, Parikh P, von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26: 3543-3551.
56. Scagliotti G, Hanna N, Fossella F et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist 2009; 14: 253-263.
57. Ciuleanu T, Brodowicz T, Zielinski C et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009; 374: 1432-1440.
58. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550.
59. Zhou C, Wu YL, Chen G et al. BEYOND: a randomized, double-blind, placebocontrolled, multicenter, phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer. J Clin Oncol 2015; 33: 2197-2204.
60. Reck M, von Pawel J, Zatloukal P et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous nonsmall- cell lung cancer: AVAil. J Clin Oncol 2009; 27: 1227-1234.
61. Lima ABC, Macedo LT, Sasse AD. Addition of bevacizumab to chemotherapy in advanced non-small cell lung cancer: a systematic review and meta-analysis. PLoS ONE 2011; 6: e22681.
62. Soria JC, Mauguen A, Reck M et al. Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol 2013; 24: 20-30.
63. Ilhan-Mutlu A, Osswald M, Liao Y et al. Bevacizumab prevents brain metastases formation in lung adenocarcinoma. Mol Cancer Ther 2016; 15: 702-770.
64. Gridelli C, Ardizzoni A, Le Chevalier T et al. Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European experts panel. Ann Oncol 2004; 15: 419-426.
65. Bronte G, Rolfo C, Passiglia F et al. What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis. Crit Rev Oncol Hematol 2015; 95: 306-317.
66. Quoix E, Zalcman G, Oster JP et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet 2011; 378: 1079-1088.
67. Lilenbaum R, Villaflor VM, Langer C et al. Single-agent versus combination chemotherapy in patients with advanced non-small cell lung cancer and a performance status of 2: prognostic factors and treatment selection based on two large randomized clinical trials. J Thorac Oncol 2009; 4: 869-874.
68. Zukin M, Barrios CH, Pereira JR et al. Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced nonsmall- cell lung cancer and Eastern Cooperative Oncology Group performance status of 2. J Clin Oncol 2013; 31: 2849-2853.
69. Gridelli C, Perrone F, Gallo C et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003; 95: 362-372.
70. Morère J-F, Bréchot J-M, Westeel V et al. Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 or 3 (IFCT-0301 study). Lung Cancer 2010; 70: 301-307.
71. Kudoh S, Takeda K, Nakagawa K et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol 2006; 24: 3657-3663.
72. Des Guetz G, Uzzan B, Nicolas P et al. Comparison of the efficacy and safety of single-agent and doublet chemotherapy in advanced non-small cell lung cancer in the elderly: a meta-analysis. Crit Rev Oncol Hematol 2012; 84: 340-349.
73. Qi WX, Tang L, He AN et al. Doublet versus single cytotoxic agent as first-line treatment for elderly patients with advanced non-small-cell lung cancer: a systematic review and meta-analysis. Lung 2012; 190: 477-485.
74. Socinski MA, Langer CJ, Okamoto I et al. Safety and efficacy of weekly nab®- paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer. Ann Oncol 2013; 24: 314-321.
75. Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 2007; 25: 1824-1831.
76. Corre R, Greillier L, Le Caër H et al. Use of a comprehensive geriatric assessment for the management of elderly patients with advanced non-small-cell lung cancer: the phase III randomized ESOGIA-GFPC-GECP 08-02 study. J Clin Oncol 2016; 34: 1476-1483.
77. Cappuzzo F, Ciuleanu T, Stelmakh L et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebocontrolled phase 3 study. Lancet Oncol 2010; 11: 521-529.
78. A study of first-line maintenance erlotinib versus erlotinib at disease progression in participants with advanced non-small cell lung cancer (NSCLC) who have not progressed following platinum. https://clinicaltrials.gov/ct2/show/NCT01328951 (5 August 2016, date last accessed)
79. Zhang X, Zang J, Xu J et al. Maintenance therapy with continuous or switch strategy in advanced non-small cell lung cancer: a systematic review and metaanalysis. Chest 2011; 140: 117-126.
80. Paz-Ares LG, de Marinis F, Dediu M et al. PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 2013; 31: 2895-2902.
81. Paz-Ares L, de Marinis F, Dediu M et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-smallcell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol 2012; 13: 247-255.
82. Barlesi F, Scherpereel A, Rittmeyer A et al. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous nonsmall- cell lung cancer: AVAPERL (MO22089). J Clin Oncol 2013; 31: 3004-3011.
83. Barlesi F, Scherpereel A, Gorbunova V et al. Maintenance bevacizumabpemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial. Ann Oncol 2014; 25: 1044-1052.
84. Pirker R, Pereira JR, Szczesna A et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009; 373: 1525-1531.
85. Di Maio M, Chiodini P, Georgoulias V et al. Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 2009; 27: 1836-1843.
86. Hanna N, Shepherd FA, Fossella FV et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589-1597.
87. Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18: 2095-2103.
88. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-132.
89. Ciuleanu T, Stelmakh L, Cicenas S et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol 2012; 13: 300-308.
90. Karampeazis A, Voutsina A, Souglakos J et al. Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study. Cancer 2013; 119: 2754-2764.
91. Garassino MC, Martelli O, Broggini M et al. Erlotinib versus docetaxel as secondline treatment of patients with advanced non-small-cell lung cancer and wildtype EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol 2013; 14: 981-988.
92. Kawaguchi T, Ando M, Asami K et al. Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced nonsmall- cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA). J Clin Oncol 2014; 32: 1902-1908.
93. Zhao N, Zhang XC, Yan HH et al. Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-smallcell lung cancer with wild-type EGFR: a meta-analysis of randomized controlled clinical trials. Lung Cancer 2014; 85: 66-73.
94. Garon EB, Ciuleanu TE, Arrieta O et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 2014; 384: 665-673.
95. Cortot A.B., Audiger-Valette C., Molinier O. et al. Weekly paclitaxel plus bevacizumab versus docetaxel as second or third line treatment in advanced non-squamous non-small cell lung cancer (NSCLC): results from the phase III study IFCT-1103 ULTIMATE. J Clin Oncol 2016; 34 (May 20 Suppl.), 2016: abstr 9005.
96. Herbst RS, Baas P, Kim DW et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016; 387: 1540-1550.
97. Rizvi NA, Mazières J, Planchard D et al. Activity and safety of nivolumab, an anti- PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 2015; 16: 257-265.
98. Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; 373: 123-135.
99. Reckamp KL, Brahmer JR, Spigel DR et al. Phase 3, randomized trial (CheckMate 017) of nivolumab (NIVO) vs docetaxel in advanced squamous (SQ) cell non-small cell lung cancer (NSCLC). J Thorac Oncol 2015; 10(Suppl. 2): S174.
100. Gralla RJ, Coon C, Taylor F et al. Evaluation of disease-related symptoms in patients with advanced squamous non-small cell lung cancer treated with nivolumab or docetaxel. J Thorac Oncol 2015; 10(Suppl. 2): S233.
101. Soria JC, Felip E, Cobo M et al. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. Lancet Oncol 2015; 16: 897-907.
102. Reck M, Kaiser R, Mellemgaard A et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol 2014; 15: 143-155.
103. Novello S, Kaiser R, Mellemgaard A et al. Analysis of patient-reported outcomes from the LUME-Lung 1 trial: a randomised, double-blind, placebo-controlled, phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer. Eur J Cancer 2015; 51: 317-326.
104. Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015; 373: 1627-1639.
105. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-957.
106. Han JY, Park K, Kim SW et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol 2012; 30: 1122-1128.
107. Inoue A, Kobayashi K, Maemondo M et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol 2013; 24: 54-59.
108. Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or chemotherapy for nonsmall- cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380-2388.
109. Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010; 11: 121-128.
110. Sequist LV, Yang JCH, Yamamoto N et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013; 31: 3327-3334.
111. Wu YL, Zhou C, Hu CP et al. Afatinib versus cisplatin plus gemcitabine for firstline treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 2014; 15: 213-222.
112. Rosell R, Carcereny E, Gervais R et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13: 239-246.
113. Inoue A, Kobayashi K, Usui K et al. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 2009; 27: 1394-1400.
114. Park K, Tan EH, O'Byrne K et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol 2016; 17: 577-589.
115. Yang JCH, Wu YL, Schuler M et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 2015; 16: 141-151.
116. Seto T, Kato T, Nishio M et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol 2014; 15: 1236-1244.
117. Stahel R, Dafni U, Gautschi O et al. A phase II trial of erlotinib (E) and bevacizumab (B) in patients with advanced non-small-cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations with and without T790 M mutation.The Spanish Lung Cancer Group (SLCG) and the European Thoracic Oncology Platform (ETOP) BELIEF trial. Ann Oncol 2015; 26 (Suppl. 6): abstr 3BA.
118. Cortot AB, Jänne PA. Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas. Eur Respir Rev 2014; 23: 356-366.
119. Yu HA, Arcila ME, Rekhtman N et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 2013; 19: 2240-2247.
120. Blakely CM, Bivona TG. Resiliency of lung cancers to EGFR inhibitor treatment unveiled, offering opportunities to divide and conquer EGFR inhibitor resistance. Cancer Discov 2012; 2: 872-875.
121. Pao W, Miller VA, Politi KA et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2: e73.
122. Yun CH, Mengwasser KE, Toms AV et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 2008; 105: 2070-2075.
123. Jänne PA, Yang JCH, Kim DW et al. AZD9291 in EGFR inhibitor-resistant nonsmall- cell lung cancer. N Engl J Med 2015; 372: 1689-1699.
124. Mitsudomi T, Tsai CM, Shepherd FA et al. AZD9291 in pre-treated T790M positive advanced NSCLC: AURA2 phase II study. J Thorac Oncol 2015; 10 (Suppl. 2): S320.
125. Soria JC, Wu YL, Nakagawa K et al. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncol 2015; 16: 990-998.
126. Douillard JY, Ostoros G, Cobo M et al. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study. Br J Cancer 2014; 110: 55-62.
127. Marchetti A, Del Grammastro M, Felicioni L et al. Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment. PLoS ONE 2014; 9: e103883.
128. Marchetti A, Palma JF, Felicioni L et al. Early prediction of response to tyrosine kinase inhibitors by quantification of EGFR mutations in plasma of NSCLC patients. J Thorac Oncol 2015; 10: 1437-1443.
129. Sueoka-Aragane N, Katakami N, Satouchi M et al. Monitoring EGFR T790 M with plasma DNA from lung cancer patients in a prospective observational study. Cancer Sci 2016; 107: 162-167.
130. Oxnard GR, Thress KS, Alden RS et al. 135O_PR: plasma genotyping for predicting benefit from osimertinib in patients (pts) with advanced NSCLC. J Thorac Oncol 2016; 11(Suppl. 4): S154.
131. Park K, Yu CJ, Kim SW et al. First-line erlotinib therapy until and beyond response evaluation criteria in solid tumors progression in Asian patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer: the ASPIRATION study. JAMA Oncol 2016; 2: 305-312.
132. Weickhardt AJ, Scheier B, Burke JM et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol 2012; 7: 1807-1814.
133. Camidge DR, Bang YJ, Kwak EL et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012; 13: 1011-1019.
134. Shaw AT, Yeap BY, Solomon BJ et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 2011; 12: 1004-1012.
135. Shaw AT, Kim DW, Nakagawa K et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013; 368: 2385-2394.
136. Blackhall F, Kim DW, Besse B et al. Patient-reported outcomes and quality of life in PROFILE 1007: a randomized trial of crizotinib compared with chemotherapy in previously treated patients with ALK-positive advanced non-small-cell lung cancer. J Thorac Oncol 2014; 9: 1625-1633.
137. Solomon BJ, Mok T, Kim DW et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014; 371: 2167-2177.
138. Costa DB, Kobayashi S, Pandya SS et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol 2011; 29: e443-e445.
139. Kim DW, Mehra R, Tan DS et al. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. Lancet Oncol 2016; 17: 452-463.
140. Ou S-HI, Ahn JS, De Petris L et al. Alectinib in crizotinib-refractory ALKrearranged non-small-cell lung cancer: a phase II global study. J Clin Oncol 2016; 34: 661-668.
141. Shaw AT, Gandhi L, Gadgeel S et al. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol 2016; 17: 234-242.
142. ALEX Study. A randomized, phase III study comparing alectinib with crizotinib in treatment-naive anaplastic lymphoma kinase-positive advanced non-small cell lung cancer participants. https://clinicaltrials.gov (5 May 2016, date last accessed).
143. Katayama R, Lovly CM, Shaw AT. Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine. Clin Cancer Res 2015; 21: 2227-2235.
144. Shaw P, Agarwal R. Pleurodesis for malignant pleural effusions. Cochrane Database Syst Rev 2004; 1: CD002916.
145. Dresler CM, Olak J, Herndon JE et al. Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. Chest 2005; 127: 909-915.
146. Davies HE, Mishra EK, Kahan BC et al. Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial. JAMA 2012; 307: 2383-2389.
147. Temel JS, Greer JA, Muzikansky A et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010; 363: 733-742.
148. Sperduto PW, Kased N, Roberge D et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 2012; 30(4): 419-425.
149. Patil CG, Pricola K, Sarmiento JM et al. Whole brain radiation therapy (WBRT) alone versus WBRT and radiosurgery for the treatment of brain metastases. Cochrane Database Syst Rev 2012; 9: CD006121.
150. Andrews DW, Scott CB, Sperduto PW et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 2004; 363: 1665-1672.
151. Soon YY, Tham IW, Lim KH et al. Surgery or radiosurgery plus whole brain radiotherapy versus surgery or radiosurgery alone for brain metastases. Cochrane Database Syst Rev 2014; 3: CD009454.
152. Yamamoto M, Serizawa T, Shuto T et al. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol 2014; 15: 387-395.
153. Sahgal A, Aoyama H, Kocher M et al. Phase 3 trials of stereotactic radiosurgery with or without whole-brain radiation therapy for 1 to 4 brain metastases: individual patient data meta-analysis. Int J Radiat Oncol Biol Phys 2015; 91: 710-717. 152.
154. Mulvenna PM, Nankivell MG, Barton R et al. Whole brain radiotherapy for brain metastases from non-small lung cancer: quality of life (QoL) and overall survival (OS) results from the UK Medical Research Council QUARTZ randomised clinical trial (ISRCTN 3826061). J Clin Oncol 2015; 33(20 Suppl); abstr 8005.
155. Tsao MN, Lloyd N, Wong RK et al. Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases. Cochrane Database Syst Rev 2012; 4: CD003869.
156. Robinet G, Thomas P, Breton JL et al. Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Français de Pneumo-Cancérologie (GFPC) Protocol 95-1. Ann Oncol 2001; 12: 59-67.
157. Lim SH, Lee JY, Lee MY et al. A randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligo-metastases in non-small-cell lung cancer. Ann Oncol 2015; 26: 762-768.
158. Vecht CJ, Hovestadt A, Verbiest HB et al. Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors: a randomized study of doses of 4, 8, and 16 mg per day. Neurology 1994; 44: 675-680.
159. Schuler M, Wu YL, Hirsh V et al. First-line afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases. J Thorac Oncol 2016; 11: 380-390.
160. Rosen LS, Gordon D, Tchekmedyian NS et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, doubleblind, placebo-controlled trial. Cancer 2004; 100: 2613-2621.
161. Henry DH, Costa L, Goldwasser F et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011; 29: 1125-1132.
162. Scagliotti GV, Hirsh V, Siena S et al. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study. J Thorac Oncol 2012; 7: 1823-1829.
163. Henry D, Vadhan-Raj S, Hirsh V et al. Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. Supp Care Cancer 2014; 22: 679-687.
164. Zacho HD, Karthigaseu NN, Fonager RF, Petersen LJ. Treatment with boneseeking radionuclides for painful bone metastases in patients with lung cancer: a systematic review. BMJ Support Palliat Care 2016; doi:10.1136/bmjspcare- 2015-000957.
165. Palma DA, Salama JK, Lo SS et al. The oligometastatic state-separating truth from wishful thinking. Nat Rev Clin Oncol 2014; 11: 549-557.
166. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol 1995; 13: 8-10.
167. Ashworth AB, Senan S, Palma DA et al. An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-smallcell lung cancer. Clin Lung Cancer 2014; 15: 346-355.
168. Detterbeck FC, Franklin WA, Nicholson AG et al. The IASLC Lung Cancer Staging Project: background data and proposed criteria to distinguish separate primary lung cancers from metastatic foci in patients with two lung tumors in the forthcoming eighth edition of the TNM classification for lung cancer. J Thorac Oncol 2016; 11: 651-665.
169. Kozower BD, Larner JM, Detterbeck FC, Jones DR. Special treatment issues in non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143(Suppl. 5): e369S-e399S.
170. Tönnies M, Pfannschmidt J, Bauer TT et al. Metastasectomy for synchronous solitary non-small cell lung cancer metastases. Ann Thorac Surg 2014; 98: 249-256.
171. Griffioen GHMJ, Lagerwaard FJ, Haasbeek CJA et al. Treatment of multiple primary lung cancers using stereotactic radiotherapy, either with or without surgery. Radiother Oncol 2013; 107: 403-408.
172. Chang JY, Liu YH, Zhu Z et al. Stereotactic ablative radiotherapy: a potentially curable approach to early stage multiple primary lung cancer. Cancer 2013; 119: 3402-3410.
173. De Ruysscher D, Wanders R, van Baardwijk A et al. Radical treatment of nonsmall- cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450). J Thorac Oncol 2012; 7: 1547-1555.
174. Cheufou DH, Welter S, Chalvatzoulis E et al. Surgery of primary lung cancer with oligometastatic m1b synchronous single brain metastasis: analysis of 37 cases. Thorac Cardiovasc Surg 2014; 62: 612-615.
175. Eberhardt WEE, Mitchell A, Crowley J et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the m descriptors in the forthcoming eighth edition of the TNM classification of lung cancer. J Thorac Oncol 2015; 10: 1515-1522.
176. Nishino M, Giobbie-Hurder A, Gargano M et al. Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin Cancer Res 2013; 19: 3936-3943.
177. Nishino M, Gargano M, Suda M et al. Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab? J Immunother Cancer 2014; 2: 17.
178. Weber J. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist 2007; 12: 864-872.
179. Saenger YM, Wolchok JD. The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases. Cancer Immun 2008; 8: 1.
180. Postel-Vinay S, Aspeslagh S, Lanoy E et al. Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies. Ann Oncol 2016; 27: 214-224.
181. Cherny NI, Sullivan R, Dafni U et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anticancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol 2015; 26: 1547-1573.
182. Dykewicz CA, Centers for Disease Control and Prevention (U.S.), Infectious Diseases Society of America, American Society of Blood and Marrow Transplantation. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis 2001; 33(2): 139-144.
183. Edge SB, Byrd DR, Compton CC (eds). AJCC Cancer Staging Handbook, 7th edition. New York, NY: Springer 2010